Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients.
Journal
Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844
Informations de publication
Date de publication:
15 08 2022
15 08 2022
Historique:
received:
08
04
2022
accepted:
03
08
2022
entrez:
15
8
2022
pubmed:
16
8
2022
medline:
18
8
2022
Statut:
epublish
Résumé
Genetic testing (GT) for hereditary cancer predisposition is traditionally performed on selected genes based on established guidelines for each cancer type. Recently, expanded GT (eGT) using large hereditary cancer gene panels uncovered hereditary predisposition in a greater proportion of patients than previously anticipated. We sought to define the diagnostic yield of eGT and its clinical relevance in a broad cancer patient population over a 5-year period. A total of 17,523 cancer patients with a broad range of solid tumors, who received eGT at Memorial Sloan Kettering Cancer Center between July 2015 to April 2020, were included in the study. The patients were unselected for current GT criteria such as cancer type, age of onset, and/or family history of disease. The diagnostic yield of eGT was determined for each cancer type. For 9187 patients with five common cancer types frequently interrogated for hereditary predisposition (breast, colorectal, ovarian, pancreatic, and prostate cancer), the rate of pathogenic/likely pathogenic (P/LP) variants in genes that have been associated with each cancer type was analyzed. The clinical implications of additional findings in genes not known to be associated with a patients' cancer type were investigated. 16.7% of patients in a broad cancer cohort had P/LP variants in hereditary cancer predisposition genes identified by eGT. The diagnostic yield of eGT in patients with breast, colorectal, ovarian, pancreatic, and prostate cancer was 17.5%, 15.3%, 24.2%, 19.4%, and 15.9%, respectively. Additionally, 8% of the patients with five common cancers had P/LP variants in genes not known to be associated with the patient's current cancer type, with 0.8% of them having such a variant that confers a high risk for another cancer type. Analysis of clinical and family histories revealed that 74% of patients with variants in genes not associated with their current cancer type but which conferred a high risk for another cancer did not meet the current GT criteria for the genes harboring these variants. One or more variants of uncertain significance were identified in 57% of the patients. Compared to targeted testing approaches, eGT can increase the yield of detection of hereditary cancer predisposition in patients with a range of tumors, allowing opportunities for enhanced surveillance and intervention. The benefits of performing eGT should be weighed against the added number of VUSs identified with this approach.
Sections du résumé
BACKGROUND
Genetic testing (GT) for hereditary cancer predisposition is traditionally performed on selected genes based on established guidelines for each cancer type. Recently, expanded GT (eGT) using large hereditary cancer gene panels uncovered hereditary predisposition in a greater proportion of patients than previously anticipated. We sought to define the diagnostic yield of eGT and its clinical relevance in a broad cancer patient population over a 5-year period.
METHODS
A total of 17,523 cancer patients with a broad range of solid tumors, who received eGT at Memorial Sloan Kettering Cancer Center between July 2015 to April 2020, were included in the study. The patients were unselected for current GT criteria such as cancer type, age of onset, and/or family history of disease. The diagnostic yield of eGT was determined for each cancer type. For 9187 patients with five common cancer types frequently interrogated for hereditary predisposition (breast, colorectal, ovarian, pancreatic, and prostate cancer), the rate of pathogenic/likely pathogenic (P/LP) variants in genes that have been associated with each cancer type was analyzed. The clinical implications of additional findings in genes not known to be associated with a patients' cancer type were investigated.
RESULTS
16.7% of patients in a broad cancer cohort had P/LP variants in hereditary cancer predisposition genes identified by eGT. The diagnostic yield of eGT in patients with breast, colorectal, ovarian, pancreatic, and prostate cancer was 17.5%, 15.3%, 24.2%, 19.4%, and 15.9%, respectively. Additionally, 8% of the patients with five common cancers had P/LP variants in genes not known to be associated with the patient's current cancer type, with 0.8% of them having such a variant that confers a high risk for another cancer type. Analysis of clinical and family histories revealed that 74% of patients with variants in genes not associated with their current cancer type but which conferred a high risk for another cancer did not meet the current GT criteria for the genes harboring these variants. One or more variants of uncertain significance were identified in 57% of the patients.
CONCLUSIONS
Compared to targeted testing approaches, eGT can increase the yield of detection of hereditary cancer predisposition in patients with a range of tumors, allowing opportunities for enhanced surveillance and intervention. The benefits of performing eGT should be weighed against the added number of VUSs identified with this approach.
Identifiants
pubmed: 35971132
doi: 10.1186/s13073-022-01101-2
pii: 10.1186/s13073-022-01101-2
pmc: PMC9377129
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
92Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA211015
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA221745
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Cancer. 2016 Dec 1;122(23):3673-3681
pubmed: 27496084
JAMA Netw Open. 2019 Oct 2;2(10):e1913900
pubmed: 31642931
Gynecol Oncol. 2017 Nov;147(2):375-380
pubmed: 28888541
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Cell. 2018 Apr 5;173(2):355-370.e14
pubmed: 29625052
Am J Hum Genet. 1999 Apr;64(4):963-70
pubmed: 10090881
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Genet Med. 2022 Feb;24(2):454-462
pubmed: 34906510
Asian Pac J Cancer Prev. 2012;13(4):1355-60
pubmed: 22799331
J Invest Dermatol. 2014 Oct;134(10):2570-2578
pubmed: 24691054
J Genet Couns. 2019 Apr;28(2):313-325
pubmed: 30636062
Nat Genet. 2002 Dec;32(4):614-21
pubmed: 12415268
JAMA Oncol. 2018 Sep 1;4(9):1228-1235
pubmed: 29978187
Eur J Cancer. 2016 Mar;55:65-73
pubmed: 26773421
Ann Oncol. 2015 Oct;26(10):2057-65
pubmed: 26153499
BMC Med Genomics. 2017 May 19;10(1):33
pubmed: 28526081
Nat Commun. 2015 Dec 22;6:10086
pubmed: 26689913
Cancer. 2017 May 15;123(10):1721-1730
pubmed: 28085182
Ann Oncol. 2013 Nov;24 Suppl 8:viii69-viii74
pubmed: 24131974
Clin Cancer Res. 2021 Mar 1;27(5):1429-1437
pubmed: 33199489
Br J Cancer. 2013 Jun 25;108(12):2455-63
pubmed: 23674091
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Clin Cancer Res. 2016 Aug 15;22(16):4087-4094
pubmed: 27083775
J Natl Compr Canc Netw. 2017 Jan;15(1):9-20
pubmed: 28040716
Hum Mutat. 2020 Jan;41(1):103-109
pubmed: 31444830
Nat Genet. 2015 Jun;47(6):643-6
pubmed: 25915596
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
N Engl J Med. 2015 Dec 10;373(24):2336-2346
pubmed: 26580448
JAMA Oncol. 2016 Jan;2(1):104-11
pubmed: 26556299
J Natl Compr Canc Netw. 2017 Dec;15(12):1465-1475
pubmed: 29223984
JNCI Cancer Spectr. 2019 Apr 27;3(2):pkz027
pubmed: 31360903
Hum Genome Var. 2018 Jun 8;5:11
pubmed: 29899996
Genet Med. 2015 Jan;17(1):70-87
pubmed: 25394175
J Clin Oncol. 2021 Aug 20;39(24):2698-2709
pubmed: 34133209
Ann Surg Oncol. 2015 Oct;22(10):3282-8
pubmed: 26219241
Cancer Discov. 2016 Nov;6(11):1267-1275
pubmed: 27655433
Clin Genet. 2015 Dec;88(6):523-9
pubmed: 25640009
Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18032-7
pubmed: 22006311
Sci Transl Med. 2015 Apr 15;7(283):283ra53
pubmed: 25877891
Nat Genet. 2011 Aug 28;43(10):1022-5
pubmed: 21874000
Trends Cancer. 2020 Jan;6(1):31-39
pubmed: 31952779
JAMA Netw Open. 2020 Oct 1;3(10):e2019452
pubmed: 33026450
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
J Clin Oncol. 2019 Feb 20;37(6):453-460
pubmed: 30526229
JAMA. 2017 Sep 5;318(9):825-835
pubmed: 28873162
J Med Genet. 2017 Nov;54(11):732-741
pubmed: 28779002
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
J Clin Oncol. 2015 Jul 20;33(21):2345-52
pubmed: 26014290
Nature. 2019 Jul;571(7766):576-579
pubmed: 31292550
Nat Genet. 1995 Oct;11(2):198-200
pubmed: 7550349
J Natl Compr Canc Netw. 2019 Sep 1;17(9):1032-1041
pubmed: 31487681
J Natl Cancer Inst. 2021 Jul 07;:
pubmed: 34240179
J Clin Oncol. 2019 Feb 1;37(4):286-295
pubmed: 30376427
J Natl Compr Canc Netw. 2021 Jan 06;19(1):77-102
pubmed: 33406487
Nat Genet. 1996 Oct;14(2):188-90
pubmed: 8841192
J Natl Compr Canc Netw. 2021 Jul 28;19(7):871-878
pubmed: 34340209
Am J Hum Genet. 2018 Mar 1;102(3):401-414
pubmed: 29478780
J Clin Oncol. 2009 Sep 10;27(26):e108-9; author reply e110
pubmed: 19652052
J Clin Oncol. 2014 Mar 1;32(7):687-98
pubmed: 24449244
Am J Hum Genet. 2021 Apr 1;108(4):696-708
pubmed: 33743207
Health Commun. 2021 May;36(5):606-615
pubmed: 32122169
JAMA Oncol. 2021 Feb 01;7(2):230-237
pubmed: 33126242
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
JAMA Oncol. 2016 May 01;2(5):616-624
pubmed: 26822237
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Ann Oncol. 2016 May;27(5):795-800
pubmed: 26787237
Eur J Cancer. 2011 Nov;47(17):2546-51
pubmed: 21807500
JAMA Oncol. 2017 Sep 01;3(9):1190-1196
pubmed: 28418444
Am J Epidemiol. 2013 Jun 1;177(11):1169-79
pubmed: 23576677
JCO Precis Oncol. 2017 Nov;1:1-12
pubmed: 35172496
J Clin Oncol. 2015 Nov 1;33(31):3660-7
pubmed: 26324357
J Community Genet. 2022 Aug;13(4):381-388
pubmed: 35616809
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Am J Hum Genet. 2021 Oct 7;108(10):1907-1923
pubmed: 34597585
Blood. 2004 May 15;103(10):3924-32
pubmed: 14726398
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821